Digest Network Come funziona
Network
/
Società
Be
Non verificato

Belenos Biosciences Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

2 comunicati stampa

Guarda tutti i comunicati
10/11/2025
Salute
Scienza
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Belenos Pipeline Updates: First Clinical Data from Lead Asset BEL512, a Long-lasting Bispecific Targeting TSLP and IL-13, Second Asset BEL536, a First-in-class Long-acting Bispecific Targeting OX40L and IL-13, Phase 1 to Start 1Q2026
Fonte
Belenos Biosciences Inc.
Emittente
Business Wire
1.00
0
10/11/2025
Industria
Salute
Scienza
Medicina - Varie
Farmaceutica
Biotecnologia
Belenos Pipeline Updates: First Clinical Data from Lead Asset BEL512, a Long-lasting Bispecific Targeting TSLP and IL-13, Second Asset BEL336, a First-in-class Long-acting Bispecific Targeting OX40L and IL-13, Phase 1 to Start 1Q2026
Fonte
Belenos Biosciences Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0